[Transplacental passage of epirubicin].
We studied the transplacental transfer of epirubicin, an anthracycline used for the treatment of different neoplastic disorders, in particular breast cancers, by in vitro perfusion of term human placenta. Placenta from women with uncomplicated pregnancy were collected immediately after vaginal delivery and put into 37 degrees C thermostated hood. Perfusion of foetal surface of the placenta by modified Earle's solution was started immediately after catheterisation at a flow rate of 6 ml/min and then so was the perfusion of the intervillous space at the rate of 12 ml/min. Samples were collected at different times after the initiation of the perfusion from arterial inflow and venous outflow respective of the maternal and foetal compartment. The transplacental transfer of epirubicin was investigated for two doses: 5 and 9 micrograms/ml. The mean transfer value of epirubicin is low (3.66 +/- 1.07%) for the two tested doses and is only slightly higher than doxorubicin transfer, which drug has provided rare accidents in the clinical reports. These results are in favour of a low placental toxicity of epirubicin. Clinical data have to be collected from pregnant women to confirm the low foetal toxicity of epirubicin.
Gaillard
B
B
Laboratoire de Pharmacocinétique et Pharmacie Clinique, UFR de Pharmacie, Bordeaux.
Leng
J J
JJ
Grellet
J
J
Ducint
D
D
Saux
M C
MC
D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000493:pharmacokinetics; D004353:Drug Evaluation, Preclinical; D015251:Epirubicin / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D021041:Placental Circulation; D011247:Pregnancy
D015251:Epirubicin; D004317:Doxorubicin
Passage transplacentaire de l'épirubicine.